Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Platelet associated immunoglobulins in primary biliary cirrhosis: a cause of thrombocytopenia?
1985
A Low-Molecular-Weight Heparinoid Compared with Unfractionated Heparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke
1992
DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE
1987
Parenteral Anticoagulants
2008
Parenteral Anticoagulants
2012 Standout
Heparin-Protein Interactions
2002 Standout
Structure and Biological Activity of Heparin
1985
Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin®) in the prophylaxis of thromboembolic complications of abdominal oncological surgery
1988
Intracellular degradation of secretion defect‐type mutants of antithrombin is inhibited by proteasomal inhibitors
1997 StandoutNobel
Prevention of Deep Vein Thrombosis after Elective Hip Surgery
1991
The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg
1988
Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis
1994
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Low Molecular Weight Heparin
1997
Low-molecular-weight Heparins for the Treatment of Venous Thromboembolism
1993
Estrogen receptor α is a major mediator of 17β-estradiol’s atheroprotective effects on lesion size in Apoe–/– mice
2001 StandoutNobel
Does protamine chloride neutralize low molecular weight heparin sufficiently?
1988
Users' Guides to the Medical Literature
1998 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
1998
A Consumer's Guide to Subgroup Analyses
1992
Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients
1990
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
1992 Standout
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo
1989
Temporal Aspects of Heparin-Induced Thrombocytopenia
2001 Standout
Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura
2000
Implications of the three-dimensional structure of .alpha.1-antitrypsin for structure and function of serpins
1989 Nobel
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
2004 Standout
Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study
1996
Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery
1993
Heparin and Low-Molecular-Weight Heparin
2004
Users' Guides to the Medical Literature
2000 Standout
Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms
2007
Mutation in blood coagulation factor V associated with resistance to activated protein C
1994 StandoutNature
Immune Thrombocytopenic Purpura
2002 Standout
Heparin-Induced Thrombocytopenia
2006 Standout
A Prospective Study of Venous Thromboembolism after Major Trauma
1994 Standout
Heparin in Acute Ischemic Stroke: The Case for a New Clinical Trial
1999
Prevention of Venous Thromboembolism
2004 Standout
Heparin and Low-Molecular-Weight Heparin
1998
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
1999 Standout
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase
1995 Standout
Improving the quality of reporting of randomized controlled trials. The CONSORT statement
1996 Standout
C1 inhibitor hinge region mutations produce dysfunction by different mechanisms
1992
Advances in the diagnosis of idiopathic thrombocytopenic purpura
2000
The Pathophysiology of Heparin-Induced Thrombocytopenia
2005
Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin
1990
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
1996
Hemorrhagic potential of combined diltiazem and recombinant tissue-type plasminogen activator administration
1993
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Comparative effects of heparin and LMW heparin on hemostasis
1991
Platelet autoantibodies in patients with chronic liver disease
1995
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Effects of Unfractionated Heparin, Dermatan Sulfate and Low Molecular Weight Heparin on Vessel Wall Permeability in Rabbitsa
1989
Conformational disease
1997
Management of Venous Thromboembolism
1996
Venous Thromboembolism in Spinal Cord Injury Patients
1992
Molecular Mechanisms of Amyloidosis
2003 Standout
Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme
1992 Standout
Changing physician performance. A systematic review of the effect of continuing medical education strategies
1995 Standout
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Clinical Outcome and Cost of Hospital vs Home Treatment of Proximal Deep Vein Thrombosis With a Low-Molecular-Weight Heparin
2000
A prospective study of protein‐specific assays used to investigate idiopathic thrombocytopenic purpura
1999
Glycosaminoglycans and the regulation of blood coagulation
1993
Low molecular weight heparin in prevention of perioperative thrombosis.
1992
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Aggresomes: A Cellular Response to Misfolded Proteins
1998 Standout
The Mode of Action of Heparin in Plasma
1988
Serpin Structure, Mechanism, and Function
2002 Standout
Antithrombin Mutation Database: 2nd (1997) Update
1997
Low Molecular Weight Heparin Therapy: Is Monitoring Needed?
1994
Potential therapeutic applications of aspirin and other cyclo‐oxygenase inhibitors.
1980
Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery.
1996
Primary Biliary Cirrhosis
1987 Standout
Low Molecular Weight Heparin
1997
Inhibition of Endothelial Regeneration by Type-Beta Transforming Growth Factor from Platelets
1986 StandoutScience
The Diagnosis of Clinically Suspected Venous Thrombosis
1984
Pregnancy-associated thrombocytopenia: pathogenesis and management
1992
Recent advances in molecular pathology
1984
Prevention of Deep Vein Thrombosis after Major Knee Surgery - A Randomized, Double-Blind Trial Comparing a Low Molecular Weight Heparin Fragment (Enoxaparin) to Placebo
1992
"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.
1983
The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis
1985
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.
1994
Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.
1989
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
2000
Prophylaxis of postoperative thromboembolism with low molecular weight heparins
1993
Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study.
1992
Effects of estradiol on platelet aggregation in mouse mesenteric arterioles and ex vivo
1985
The Comparative Effects of Recombinant Hirudin (CGP 39393) and Standard Heparin on Thrombus Growth in Rabbits
1990
A comparison of the anti thrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation
1984
A diagnostic test for heparin-induced thrombocytopenia
1986 Standout
The Relationship between Anti-Factor Xa Level and Clinical Outcome in Patients Receiving Enoxaparine Low Molecular Weight Heparin to Prevent Deep Vein Thrombosis after Hip Replacement
1989
Prospective evaluation of the clinical usefulness of an antigen- specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias
1996
Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis
1986
A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip Surgery
1986
Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect
1986
The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway
2001 StandoutNobel
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Neutralization of enoxaparine-induced bleeding by protamine sulfate.
1990
Prevention of Postoperative Venous Thrombosis: A Randomized Trial Comparing Unfractionated Heparin with Low Molecular Weight Heparin in Patients Undergoing Total Hip Replacement
1988
Low-Molecular-Weight Heparins
1997 Standout
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
1994
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
2001 Standout
Thromboembolic Prophylaxis in Moderate‐Risk Patients Undergoing Elective Abdominal Surgery: Decision and Cost‐Effectiveness Analyses
1996
Inhibition of low molecular weight heparin by protamine chloride in vivo
1985
The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma
1988
Comparison of Unfractionated Versus Low Molecular Weight Heparin for Deep Vein Thrombosis Prophylaxis During Breast and Pelvic Cancer Surgery: Efficacy, Safety, and Follow-up
1998
Heparin-Associated Thrombocytopenia
1984
Evidence for the Effectiveness of CME
1992 Standout
Subcutaneous Heparin and Postoperative Wound Hematomas
1986
Functions of Cell Surface Heparan Sulfate Proteoglycans
1999 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia
2001 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
1995
The Pathogenesis of Atherosclerosis — An Update
1986 Standout
The molecular immunology of human platelet proteins
1992
Nifedipine
1995 Standout
Vessel injury, platelet adherence, and platelet survival.
1983
Subcutaneous Low-Molecular-Weight Heparin Compared With Continuous IntravenoUnfractionated Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis
1993
Works of CJ Carter being referenced
The relationship among platelet-associated IgG, platelet lifespan, and reticuloendothelial cell function
1984
The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits
1982
Sex differences in the antithrombotic effects of aspirin
1978
Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity
1988
The diagnostic value of the fibrinogen/fibrin fragment E antigen assay in clinically suspected deep vein thrombosis
1982
Decreased platelet thrombogenecity in association with increased platelet turnover and vascular damage
1979
Sex differences in the antithrombotic effects of aspirin
1978
Sex-related differences in platelet aggregation: influence of the hematocrit
1980
Decreased platelet thrombogenecity in association with increased platelet turnover and vascular damage
1979
A prospective study of the usefulness of the measurement of platelet- associated IgG for the diagnosis of idiopathic thrombocytopenic purpura
1982
Drug-induced thrombocytopenia is associated with increased binding of IgG to platelets both in vivo and in vitro
1981
A prospective study of the usefulness of the measurement of platelet- associated IgG for the diagnosis of idiopathic thrombocytopenic purpura
1982
The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits
1982